Michaela Ridzonova
Shares of $NOVO-B.CO (Novo Nordisk B A/S) plummeted after the Wegovy-maker posted fourth-quarter results and issued a sales warning for 2026. The company stated adjusted sales growth for 2026, which excludes revenue from the reversal of 340B provisions, is expected to be -5 to -13% at CER. In 2025, sales grew 10%. The company stated the lower outlook is related to lower prices due to the "Most Favoured Nations" agreement in the U.S., the patent expiry of the semaglutide molecule in certain IO markets, as well as competition. Shares of Novo closed 14.6% lower in New York trading, while its Copenhagen-listed shares plunged around 16% on Wednesday. Source: www.investing.com/news/stock-market-news/novo-nordisk-shares-plunge-amid-lower-2026-sales-outlook-4482565
null
.